You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Belgian home testing company said it will use the money to initiate clinical development for a urine-based self-test for chlamydia and gonorrhea.
The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.
The financing will be used for the development and clinical validation of oncology panels for treatment selection and patient monitoring with an initial focus on NSCLC.
The money will be used for research and development, building a clinical laboratory network, and seeking regulatory approval.
The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.
Tangen will use the proceeds to scale up manufacturing for its SARS-CoV-2 point-of-care test and accelerate development of a panel test including SARS-CoV-2 targets.
The firm will use the proceeds to support commercialization, regulatory, and product development activities, as well as for general working capital purposes.
Koch Disruptive Technologies, Longliv Ventures, and OurCrowd participated in the round, bringing the firm's total funding to date to more than $124 million.
The firm will use the proceeds to advance its liquid biopsy early cancer detection assay CancerSEEK in an FDA registrational trial.
BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.